Endo T Baseline Followup Measurement

---
name: endo-t-baseline-followup-measurement
description: Recommends measuring testosterone levels at baseline and after 3–6 weeks of initial treatment to assess for patient overuse or excessive dosing. Triggered when initiating testosterone therapy in women with hypoactive sexual desire disorder (HSDD) to verify levels remain within physiological range and avoid supratherapeutic dosing.
---

# Suggest baseline and early follow-up testosterone measurement

## STEP 1 — Gather Information
Confirm diagnosis of hypoactive sexual desire disorder (HSDD) in a postmenopausal woman and document intent to initiate testosterone therapy. → Action: Proceed to contraindication assessment.

## STEP 2 — Rule In / Rule Out
Assess for absolute contraindications to testosterone therapy (e.g., androgen-sensitive malignancies, uncontrolled cardiovascular disease, pregnancy). → If no contraindications, rule in for baseline T measurement; if contraindications present, rule out and halt therapy initiation.

## STEP 3 — Classify or Stratify
Measure baseline total testosterone level using LC-MS/MS or validated assay and classify as subphysiological (<LLN), physiological (within reference range), or supratherapeutic (>ULN) for premenopausal women. → Action: Record baseline value and classification.

## STEP 4 — Decide
If baseline is physiological or subphysiological, initiate testosterone therapy at physiological dose and schedule follow-up T measurement at 3–6 weeks; if baseline is supratherapeutic, withhold therapy and investigate for exogenous androgen use or pathology.

## Clinical Guardrails / Mimics / Pitfalls
Do not use supra-physiological testosterone doses; avoid oral methyltestosterone due to hepatic toxicity risks; monitor for androgenic adverse effects (acne, hirsutism, voice changes) at each visit; rely on LC-MS/MS for accurate low-level testosterone measurement in women; do not initiate therapy if baseline T is supratherapeutic without investigating etiology.

## Concrete Clinical Example
A 55-year-old postmenopausal woman with HSDD begins transdermal testosterone therapy. Baseline T: 12 ng/dL (reference range 8-40 ng/dL). At 5-week follow-up, T: 50 ng/dL (supratherapeutic). Dose reduced by 50%; repeat T at 4 weeks shows 22 ng/dL, within physiological range.

**Source:** Androgen Therapy in Women: A Reappraisal: An Endocrine Society Clinical Practice Guideline, Endocrine Society, 2014, 10.1210/jc.2014-2260